September 28, 2011 – Calypso Medical Technologies Inc., developer of real-time localization technology used for precise tumor tracking, announced that the U.S. Food and Drug Administration (FDA) granted investigational device exemption (IDE) approval for its clinical study evaluating real-time tracking of lung cancer tumors during radiation delivery. Patient enrollment is planned at Washington University in St. Louis, and the Cancer Treatment Centers of America in Tulsa, Oklahoma. Investigators in the United States will implant three anchored Beacon transponders in patients’ lungs and use the Calypso System to precisely track tumor location and movement during lung cancer radiation therapy.

“We are very pleased to see Calypso begin the U.S. portion of this important clinical study to assess the clinical experience and safety of anchored transponders in the small airways of patients with lung cancer,” said Daniel Nader, DO, FCCP, national clinical director, pulmonary/critical care and interventional pulmonologist at the Cancer Treatment Centers of America at Southwestern Regional Medical Center in Tulsa, Okla. “The five-year survival rate for lung cancer is grim at just 16 percent; however, with the Calypso System’s ability to track this high-velocity repetitive motion, treatment options for lung cancer patients may expand to include earlier and more aggressive radiation treatment.”

Calypso began the pivotal study in October 2010 at Tygerberg Hospital, affiliated with the University of Stellenbosch, in South Africa, located outside of Cape Town. The multi-center study is also underway at the University of Heidelberg in Germany, and the University Hospital Basel in Switzerland. Early data on the implantation of the electromagnetic transponders in lung cancer patients, and the use of the Calypso System for real-time tracking in these patients will be presented at the upcoming American Society of Radiation Oncology (ASTRO) meeting in Miami.

“There is a clear need for dose-escalation in curative radiation therapy for most patients suffering from locally confined early stage lung cancer,” said Frank Zimmermann, M.D., principal investigator and head of the Department of Radiation Oncology at the University Hospital Basel in Switzerland. “Ideal techniques allow the guidance of the highly focused beams in real-time in spite of the complexity and inconstancy of tumor motion in the lung. They may also enable higher dose therapy than has been possible with more conventional stereotactic techniques.

“The anchored Beacon transponders used by the Calypso System provide us with immediate and precise information regarding the location and movement of the tumor, and this may help make radiation a feasible curative option for a broader group of patients suffering from lung cancer.”

Engineers at Calypso developed the proprietary Beacon transponders for use in lung cancer patients by including an anchoring feature that provides stability in the airways of the lung. To account for the motion associated with lung tumors and ensure that the treatment target stays within the path of the radiation beam, clinicians add a treatment margin or envelope of healthy tissue around the tumor, which includes all of the possible directions the tumor can move as the patient breathes. In order to keep the envelope of healthy tissue being irradiated as small as possible, physicians must be able to accurately track the location of the tumor in real time. Because Calypso’s technology provides this information continuously throughout each treatment session, more radiation is delivered to the tumor, which may improve outcomes. At the same time, less radiation is delivered to healthy tissue, which may lower the incidence of side effects.

According to the American Cancer Society’s 2011 lung cancer statistics, an estimated 221,130 new cases of lung cancer will be diagnosed this year (115,060 among men and 106,070 among women), and the associated mortality at 156,940 will be higher than that of breast, prostate and colorectal cancers combined. Despite the very serious prognosis of lung cancer, treatment progress is being made. More than 400,000 people alive today have been diagnosed with lung cancer at some point.

The Beacon transponders, currently cleared by the FDA for permanent implantation in the prostate and prostatic bed to provide precise, continuous information on the tumor location during radiation therapy, have been engineered to allow for safe implantation in the lung using a standard bronchoscope and proprietary delivery catheter. Calypso’s electromagnetic technology is the only non-ionizing guidance solution that uses internal markers to keep the radiation beam precisely focused on the tumor in real-time, without adding unnecessary radiation. Used in prostate cancer radiation therapy, the Calypso System has been used to treat more than 10,000 patients worldwide.

For more information: www.calypsomedical.com

 

Related Content

News | Nuclear Imaging

January 26, 2022 — On January 24, the Emergency Response Team (ERT) of Nuclear Medicine Europe (NMEu) communicated that ...

Time January 26, 2022
arrow
News | Prostate Cancer

January 19, 2022 — For the first time, researchers led by a team from the UCLA Jonsson Comprehensive Cancer Center used ...

Time January 19, 2022
arrow
News | Radiation Therapy

January 13, 2022 — A new clinical guideline from the American Society for Radiation Oncology (ASTRO) provides guidance ...

Time January 13, 2022
arrow
News | Radiation Therapy

January 10, 2022 — Nanobiotix, a late-stage clinical biotechnology company pioneering physics-based approaches to expand ...

Time January 10, 2022
arrow
News | Radiation Oncology

January 7, 2022 — A Case Western Reserve University-led team of scientists has used Artificial Intelligence (AI) to ...

Time January 07, 2022
arrow
News | Proton Therapy

January 3, 2022 — IBA (Ion Beam Applications S.A., EURONEXT), the world leader in particle accelerator technology and ...

Time January 03, 2022
arrow
News | Radiation Oncology

December 30, 2021 — IBA (Ion Beam Applications S.A), a world leader in particle accelerator technology, announced the ...

Time December 30, 2021
arrow
News | Radiation Therapy

December 29, 2021 — Researchers at the University of Surrey have identified key design rules for making curved X-ray ...

Time December 29, 2021
arrow
Feature | Radiology Business | By Melinda Taschetta-Millane

Here is a list of the Top 10 most read pieces of content on ITNonline.com from the month of December 2021. This is based ...

Time December 23, 2021
arrow
News | Radiation Therapy

December 22, 2021 — Surgeons at Henry Ford Health System have treated a patient with a recurrent brain tumor by ...

Time December 22, 2021
arrow
Subscribe Now